India 'refuses' to progress Novartis Galvumet patent application
This article was originally published in Scrip
The Indian patent office has declined to "proceed further" with Novartis' application for vildagliptin and metformin in a single formulation (Galvumet) citing lack of inventive step and objections around the "sufficiency of disclosure".
You may also be interested in...
Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.
Charges of price collusion pertaining to Novartis’ Galvus are the latest in a string of allegations that have rocked the pharmaceutical industry in India over the recent past, though the company claims it has not flouted the law. Industry is also under fire for ‘suspected’ deviations from mandated price caps for over 600 medicines – a charge seen widening the trust deficit.
Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.